GO
Loading...

Endo Health Solutions Inc

More

  • Sept 22- Auxilium Pharmaceuticals Inc said its board had determined that Endo International Plc's $2.2 billion takeover offer "significantly undervalues" the company, but left the door open for talks on a possible deal.

  • Sept 22- Auxilium Pharmaceuticals Inc said its board had determined that Endo International Plc's offer "significantly undervalues" the company. Auxilium said in June that it would buy QLT for $346 million, in a deal aimed at cutting its tax bill by moving its headquarters to lower-tax British Columbia, Canada.

  • Auxilium Pharma rejects Endo's takeover offer Monday, 22 Sep 2014 | 7:45 AM ET

    CHESTERBROOK, Pa.— Auxilium Pharmaceuticals Inc.' s board has rejected an approximately $1.4 billion unsolicited takeover offer from Ireland's Endo International PLC. Auxilium, based in Chesterbrook, Pennsylvania, had adopted a one-year "poison pill" shareholder rights plan last week.

  • Sept 22- Auxilium Pharmaceuticals Inc said its board had determined that Endo International Plc's offer "significantly undervalues" the company. Endo made an unsolicited offer last week to buy Auxilium for about $2.2 billion. Auxilium's board also reiterated on Monday that it backed the company's offer to buy Canadian eye drug maker QLT Inc.

  • The drug, developed by Vivus Inc, is marketed in the United States and Canada by Auxilium Pharmaceuticals Inc. Vivus' stock was up about 13 percent at $4.40 in afternoon trading.

  • The drug was developed by Auxilium Pharmaceuticals Inc and Vivus Inc.. Vivus owns the worldwide development and commercial rights to Stendra for use in sexual dysfunction, with the exception of certain Asian countries in the Pacific Rim.

  • The drug, developed by Vivus Inc, is marketed in the United States and Canada by Auxilium Pharmaceuticals Inc. Vivus' stock was up about 13 percent at $4.40 in afternoon trading.

  • Sept 18- An erectile dysfunction drug that reduces by half the time patients need to take the pill before sexual activity has been approved by the U.S. Food and Drug Administration.

  • US STOCKS-Wall St to open flat, eyes on Fed statement Wednesday, 17 Sep 2014 | 9:15 AM ET

    NEW YORK, Sept 17- U.S. stocks were set to open little changed on Wednesday ahead of a key statement by the Federal Reserve which is expected to provide clues on the next monetary policy move by the U.S. central bank.

  • NEW YORK, Sept 17- Auxilium Pharmaceuticals shares surged in brisk premarket trading Wednesday, a day after receiving an unsolicited offer from Endo International. Analysts said the offer could complicate Auxilium's buyout of Canadian eye drug maker QLT Inc, whose U.S. shares were down 11.3 percent in light trading.

  • Sept 17- Auxilium Pharmaceuticals Inc said it would not withdraw its offer to buy Canadian eye drug maker QLT Inc and adopted a poison pill, a day after receiving an unsolicited buyout offer from Endo International Plc.

  • Sept 17- Auxilium Pharmaceuticals Inc adopted a poison pill with a 15 percent trigger, a day after an unsolicited $2.2 billion buyout offer from Endo International Plc.

  • Sept 16- Endo International Plc made an unsolicited offer to buy Auxilium Pharmaceuticals Inc for about $2.2 billion, which analysts said could complicate Auxilium's buyout of Canadian eye drug maker QLT Inc.

  • Sept 16- Specialty healthcare company Endo International Plc offered to buy Auxilium Pharmaceuticals Inc for about $2.2 billion in cash and stock to expand its men's healthcare products business.

  • Endo offers to buy Auxilium Pharma for about $2.2 bln Tuesday, 16 Sep 2014 | 5:01 PM ET

    Sept 16- Endo International Plc offered to acquire Auxilium Pharmaceuticals Inc for about $2.2 billion in cash and stock. The offer of $28.10 per share represents a premium of 30.6 percent to Auxilium's Tuesday closing price of $21.52 on the Nasdaq. Endo said it intends to fund the transaction through cash on hand and debt financing.

  • Aug 27- Repros Therapeutics Inc said its experimental drug to treat low testosterone was superior to a leading marketed gel and a placebo in the first of two identical studies. Patients who were given the drug, Androxal, experienced superiority in sperm concentration compared with those who used Abbvie Inc's AndroGel, said the company.

  • Aug 27- Repros Therapeutics Inc said its experimental drug to treat low testosterone was superior to a leading marketed gel and a placebo in two studies. Patients who were given the drug, Androxal, experienced superiority in sperm concentration compared with those who used Abbvie Inc's AndroGel, said the company.

  • July 31- Specialty healthcare company Endo International Plc reported a better-than-expected quarterly profit, helped by a 60 percent surge in U.S. generic sales, and raised its full-year forecast for the second time this year.

  • Endo tops Wall Street quarterly estimates Thursday, 31 Jul 2014 | 7:09 AM ET

    July 31- Specialty healthcare company Endo International Plc reported a better-than-expected quarterly profit, helped by a 60 percent rise in U.S. generic sales, and it raised its full-year forecast.

  • July 11- Medical device maker Covidien Plc said it recorded a pre-tax charge of about $180 million for the third quarter, related to litigation against some manufacturers of pelvic mesh products. Covidien said it was indemnifying the manufacturer on certain claims.